- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
- Supernus Announces First Quarter 2024 Financial Results
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
As of last trade, Supernus Pharmaceuticals Inc (0LB2:LSE) traded at 26.21, 16.28% above the 52 week low of 22.54 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 26.21 |
Average volume | 132.50 |
---|---|
Shares outstanding | 54.97m |
Free float | 52.21m |
P/E (TTM) | -- |
Market cap | 1.51bn USD |
EPS (TTM) | -0.2843 USD |
Data delayed at least 20 minutes, as of Jun 07 2024 18:20 BST.
More ▼